- Home
- ESLA vs ANVS Comparison
ESLA vs ANVS Comparison
Compare ESLA & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESLA | ANVS |
|---|---|---|
| Founded | 2021 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.5M | 69.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | ESLA | ANVS |
|---|---|---|
| Price | $1.15 | $1.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $8.00 | ★ $13.50 |
| AVG Volume (30 Days) | 28.4K | ★ 1.2M |
| Earning Date | 05-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.78 | $1.54 |
| 52 Week High | $3.15 | $5.50 |
Technical Indicators
Market Signals| Indicator | ESLA | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 42.52 | 44.61 |
| Support Level | $0.98 | $1.79 |
| Resistance Level | $1.31 | $2.38 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 50.00 | 22.83 |
Price Performance
Historical ComparisonAbout ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.